On January 9, the global pharmaceutical giant Eli Lilly announced on its official Weibo that Huzur Devletsah became the new president and general manager of Eli Lilly China and the first female head of Eli Lilly China. With 25 years of experienceAccording to reports, Huzur Devletsah joined Eli Lilly as early as 1998 and has 25 years of leadership experience in headquarters and different geographies. He has served as President and General Manager of Eli Lilly Italy, Central and Eastern Europe, Russia CIS countries and Israel, as well as Managing Director of the Middle East, Senior Director of Strategy and Operations of Eli Lilly Biopharma, and Head of International Diabetes Division, with responsibilities covering sales, strategic planning, public affairs and other areas. 
*: Eli Lilly China's official Weibo For the new head of Eli Lilly China, Huzur Devletsah said that he will continue to strengthen cooperation with China**, associations and enterprises, "China's industrial, intelligent and economic development speed is difficult for other countries in the world to achieve, and the improvement of Chinese's per capita living standards, the improvement of demand for a better life, and the acceleration of population aging also indicate that the burden on the shoulders of every medical person is getting heavier and heavier." Eli Lilly is a century-old company with a mission to improve people's well-being through drug discovery and innovation, and Eli Lilly China will take concrete actions to accelerate product launch and rapid transformation to reach Chinese patients faster. ”Actively expand business in ChinaIt is worth noting that before Huzur Devletsah, many leaders of Eli Lilly China have publicly expressed their optimism about the Chinese market. For example, Julio Gay-ger, former president and general manager, once said that China's efforts in innovation protection and other aspects have strengthened Eli Lilly's confidence in investing in China. We are optimistic about the long-term development of China's pharmaceutical market, and it is expected that more innovative drugs will be introduced into China in the future. According to the data, Eli Lilly was founded in 1876 and is headquartered in Indianapolis, USA, mainly engaged in drug research and development, production and sales, and is in a leading position in the fields of diabetes, oncology, immunity, pain and neurodegenerative diseases, and has been on the Fortune 500 list several times. It is understood that Eli Lilly has R&D institutions and factories in many countries around the world, and has also actively expanded its business in China in recent years. In December last year, the National Health Insurance Administration announced the 2023 version of the National Medical Insurance Drug List, and a number of Eli Lilly and Company's products (including new indications) were included. In addition, the company has invested in the construction of three production bases in Suzhou, with a total investment of 4 billion yuan. As Eli Lilly's only manufacturing base in China, Eli Lilly Suzhou's canned products are also accelerating the opening of overseas markets, according to the news released by Suzhou Industrial Park last year, in 2022, Eli Lilly Suzhou's European export volume and corresponding sales increased by more than three times compared with 2021;In the first half of 2023, Eli Lilly Suzhou's total exports exceeded 100 million yuan. According to Eli Lilly's financial report for the third quarter of 2023, in the third quarter of 2023, the company's revenue reached $9.5 billion, a year-on-year increase of 37%. The cumulative revenue in the first three quarters was 247US$700 million, a year-on-year increase of 17%;Net profit 30$5.1 billion. In terms of stock price performance, as of January 8**, Eli Lilly was trading at 626 per share$03, the stock price has risen by 483 in five years since 201928%, and there is also an increase of 71% since 2023. The company's market capitalization has also reached new highs, and in May last year, it surpassed Johnson & Johnson to become the world's most valuable pharmaceutical company, and the latest market value has reached $594.3 billion. 
Edit: Captain's Review: Muyu.